Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026)
Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | 99.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.82% |
| Dec 31, 2025 | 99.79% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | -7.80% |
| Mar 31, 2025 | 99.82% |
| Dec 31, 2024 | 30.78% |
| Sep 30, 2024 | 14.90% |
| Jun 30, 2024 | 14.14% |
| Mar 31, 2024 | 35.28% |
| Dec 31, 2023 | -0.97% |
| Sep 30, 2023 | 16.75% |
| Jun 30, 2023 | 28.67% |
| Mar 31, 2023 | -51.80% |
| Dec 31, 2022 | 10.35% |
| Sep 30, 2022 | -21.18% |
| Jun 30, 2022 | 17.26% |
| Mar 31, 2022 | -27.91% |
| Dec 31, 2021 | -2.70% |
| Sep 30, 2021 | -17.94% |
| Jun 30, 2021 | -76.53% |